Breathe Well Live Well
|
Palatin Technologies, Inc. Issued U.S. Patent for Key Component in PL-3994 …
DigitalJournal.com (press release) A small molecule mimic claimed in the issued patent is used in making PL-3994, Palatin's lead peptide mimetic natriuretic peptide receptor A agonist, which is in development for treatment of acute exacerbations of asthma, heart failure and refractory … |
View full post on asthma – Google News
|
Palatin Technologies, Inc. Issued U.S. Patent for Key Component in PL-3994 …
PR Newswire (press release) A small molecule mimic claimed in the issued patent is used in making PL-3994, Palatin's lead peptide mimetic natriuretic peptide receptor A agonist, which is in development for treatment of acute exacerbations of asthma, heart failure and refractory … |
View full post on asthma – Google News
|
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
PR Newswire (press release) Palatin has started discussions with a number of potential development and marketing partners for PL-3994 for acute asthma, which would include the proof-of-concept human trial for asthma using a subcutaneously administered formulation and development … Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript |
View full post on asthma – Google News
|
Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript
Seeking Alpha On the next program, I would like to talk about is PL-3994, our natriuretic peptide receptor agonist in development as a treatment for acute exacerbations of asthma. Acute exacerbations of asthma, also called acute severe asthma, is an ongoing asthma … Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results |
View full post on asthma – Google News
|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
AUTO-MOBI.info (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News
|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
DigitalJournal.com (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News
|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
PR Newswire (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News
|
Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma
Genetic Engineering News It intends to use the proceeds for working capital and general corporate purposes including its clinical trial program with bremelanotide for female sexual dysfunction (FSD), its PL-3994 programs for asthma, and for the preclinical development of … |
View full post on asthma – Google News
|
Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split
Wall Street Journal Palatin has been developing bremelanotide for male and female sexual dysfunction and PL-3994 for acute severe asthma. The company plans to submit plans for … Palatin Announces Strategic Realignment of Operations Palatin Reducing Workforce By 50%; To Effect 1-for-10 Reverse Stock Split … |
View full post on asthma – Google News